Breaking News Instant updates and real-time market news.

ATUS

Altice USA

$17.94

(0.00%)

, SOGO

Sogou

$7.92

-0.31 (-3.77%)

08:45
09/05/18
09/05
08:45
09/05/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Altice USA (ATUS) 1.12% +0.87, Sogou (SOGO) 18.96% +0.59, Market Vectors Semiconductor (SMH) 1.39% +0.23, TransEnterix (TRXC) 34.28% +0.15, Affimed NV (AFMD) 5.90% +0.14, Blue Apron (APRN) 20.56% +0.07, Fortive (FTV) 0.49% +0.05, GTT Communications (GTT) 2.94% +0.05, First Majestic (AG) 2.28% +0.01, and WPX Energy (WPX) 0.82% +0.01.

ATUS

Altice USA

$17.94

(0.00%)

SOGO

Sogou

$7.92

-0.31 (-3.77%)

SMH

Market Vectors Semiconductor

$109.68

0.75 (0.69%)

TRXC

TransEnterix

$5.97

0.17 (2.93%)

AFMD

Affimed N.V.

$5.55

0.125 (2.30%)

APRN

Blue Apron

$1.94

-0.085 (-4.20%)

FTV

Fortive

$83.46

-0.54 (-0.64%)

GTT

GTT Communications

$41.90

-1.075 (-2.50%)

AG

First Majestic

$5.37

-0.19 (-3.42%)

WPX

WPX Energy

$18.40

-0.67 (-3.51%)

  • 05

    Sep

  • 05

    Sep

  • 05

    Sep

  • 06

    Sep

  • 24

    Sep

ATUS Altice USA
$17.94

(0.00%)

08/09/18
RBCM
08/09/18
NO CHANGE
Target $25
RBCM
Outperform
Altice USA price target lowered to $25 from $31 at RBC Capital
RBC Capital analyst Jonathan Atkin lowered his price target on Altice USA to $25 after its lower than expected Q2 EBITDA, citing pressure coming from one-time items. The analyst keeps his Outperform rating, noting that revenue and adjusted EBITDA should accelerate in the second half of the year with pricing increases and political advertising revenue.
07/10/18
FBCO
07/10/18
INITIATION
Target $21
FBCO
Outperform
Altice USA initiated with an Outperform at Credit Suisse
Credit Suisse analyst Doug Mitchelson initiated Altice USA with an Outperform and $21 price target citing an expected 2H 2018 revenue acceleration with a potential return of stock repurchases within the year.
07/09/18
GUGG
07/09/18
UPGRADE
Target $24
GUGG
Buy
Altice USA upgraded to Buy at Guggenheim on valuation
As reported earlier, Guggenheim analyst Michael Morris upgraded Altice USA to Buy from Neutral and raised his price target to $24 from $21. Morris notes that he remains bearish on the the overall trend of heightened direct and collateral pricing pressure from competitive virtual video providers, along with sustained pressure from maturing broadband tempering enthusiasm for cable investment. However, the analyst also states that the "valuation multiple contraction across the pay-TV industry has created a particularly attractive investment opportunity in Altice USA" given that investor interest in the company had been tempered by the previously-complicated ownership structure and limited share float. Morris believes that those concerns have been "over-emphasized" in the company's current valuation.
07/09/18
GUGG
07/09/18
UPGRADE
GUGG
Buy
Altice USA upgraded to Buy from Neutral at Guggenheim
SOGO Sogou
$7.92

-0.31 (-3.77%)

12/07/17
12/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sogou (SOGO) initiated with an Overweight at JPMorgan. 2. Amag Pharmaceuticals (AMAG) initiated with a Neutral at B. Riley FBR. 3. Akebia (AKBA) initiated with a Buy at BTIG. 4. Synnex (SNX) initiated with a Buy at SunTrust. 5. Cancer Genetics (CGIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/15/18
DBAB
03/15/18
INITIATION
Target $8.2
DBAB
Hold
Sogou initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Han Joon Kim started Sogou with a Hold rating and $8.20 price target. The analyst believes the shares do "not have a lot of room for mistakes" at current valuation levels. He thinks Sogou is a business "worth monitoring within the context of the constantly evolving China internet industry."
07/31/18
DBAB
07/31/18
DOWNGRADE
Target $5.6
DBAB
Sell
Sogou downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Hanjoon Kim downgraded Sogou to Sell and lowered his price target for the shares to $5.60 from $7.70. The analyst calls the company's Q2 results a "sobering start" to the Chinese Internet earnings season.
08/01/18
JPMS
08/01/18
DOWNGRADE
JPMS
Neutral
Sogou downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Alex Yao downgraded Sogou to Neutral citing a weakening earnings outlook following the company's Q2 results.
SMH Market Vectors Semiconductor
$109.68

0.75 (0.69%)

TRXC TransEnterix
$5.97

0.17 (2.93%)

05/29/18
STFL
05/29/18
NO CHANGE
Target $4
STFL
Buy
TransEnterix new indications double Senhance's procedure base, says Stifel
Stifel analyst Rick Wise said the FDA approval for TransEnterix to market its Senhance robotic surgical system for laparoscopic inguinal hernia and gallbladder removal came slightly earlier than expected and nearly doubles Senhance's procedure base to 3 million procedures annually. While Wise is not increasing his projections, he thinks the new "critical mass" of indications could accelerate TransEnterix's commercial adoption trajectory over time, he tells investors. The analyst keeps a Buy rating and $4 price target on TransEnterix shares.
05/29/18
LTCO
05/29/18
DOWNGRADE
LTCO
Neutral
TransEnterix downgraded to Neutral from Buy at Ladenburg
05/29/18
05/29/18
DOWNGRADE
Target $4

Neutral
TransEnterix downgraded to Neutral with $4 price target at Ladenburg
As previously reported, Ladenburg analyst Jeffrey Cohen downgraded TransEnterix to Neutral from Buy citing valuation with the stock having rallied after the company received FDA approval for expanded indications that now mean the Senhance system is approved for the most commonly performed surgeries in more than 95% of hospitals nationally. Cohen raised his price target for TransEnterix to $4 from $3.50.
06/28/18
BTIG
06/28/18
DOWNGRADE
BTIG
Neutral
TransEnterix downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded TransEnterix to Neutral citing the "rapid" rise in shares.
AFMD Affimed N.V.
$5.55

0.125 (2.30%)

08/28/18
JEFF
08/28/18
UPGRADE
JEFF
Buy
Affimed N.V. upgraded to Buy from Hold at Jefferies
08/28/18
BMOC
08/28/18
NO CHANGE
Target $5
BMOC
Outperform
Affimed N.V. price target raised to $5 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Affimed to $5 from $4 and kept his Outperform rating, citing the impact of the $96M upfront payment from strategic collaborator Genentech on NK-cell engager based therapy. The analyst adds that in addition to financing risk reduction, the deal provides "big pharma validation" for Affimed's ROCK technology platform.
08/28/18
08/28/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. RH (RH) upgraded to Accumulate from Hold at Gordon Haskett. 2. Estee Lauder (EL) and Coty (COTY) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. First Business Financial (FBIZ) upgraded to Buy from Neutral at DA Davidson with analyst Kevin Reevey saying the current trading level on the stock presents an attractive entry point after its 10% month-to-date decline and a 19% retreat from its 52-week highs. 4. Regency Centers (REG) upgraded to Buy from Hold at Deutsche Bank with analyst Derek Johnston saying "clear signs" of a retail recovery has fueled the rally in strip real estate investment trusts in recent weeks. 5. Affimed N.V. (AFMD) upgraded to Buy from Hold at Jefferies with analyst Maury Raycroft saying its collaboration with Roche Group's (RHHBY) Genentech to develop and commercialize novel NK cell engagers indicate the intrinsic value in Affimed's platform and approach. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/28/18
08/28/18
UPGRADE
Target $4

Buy
Affimed N.V. upgraded to Buy after Roche collaboration at Jefferies
As previously reported, Jefferies analyst Maury Raycroft upgraded Affimed N.V. (AFMD) to Buy from Hold, stating that its collaboration with Roche Group's (RHHBY) Genentech to develop and commercialize novel NK cell engagers indicate the intrinsic value in Affimed's platform and approach. Affimed will retain its AFM13 and AFM11 wholly-owned clinical programs and can still partner with other companies, noted Raycroft, who raised his price target on Affimed shares to $4.00 from $1.80.
APRN Blue Apron
$1.94

-0.085 (-4.20%)

02/16/18
NRCS
02/16/18
UPGRADE
NRCS
Neutral
Blue Apron upgraded to Neutral from Sell at Northcoast
02/16/18
02/16/18
UPGRADE

Neutral
Blue Apron upgraded to Neutral on retail partnership potential at Northcoast
As previously reported, Northcoast analyst Charles Cerankosky upgraded Blue Apron to Neutral from Sell. He noted that management is suggesting the company could be at breakeven EBITDA by year end, though he "is far less optimistic." Still, given the pressure of its negative cash flow, he thinks Blue Apron will explore a retail distribution partnership, which could have a potential headline benefit. However, Cerankosky added that he expects that even if such a retail distribution partnership was struck, he believes "disappointing sales at retail would likely force such a relationship to die quickly."
07/13/18
KEYB
07/13/18
NO CHANGE
KEYB
Sector Weight
Blue Apron's Costco test 'progressign well,' says KeyBanc
KeyBanc analyst Edward Yruma told investors in a research note that Blue Apron's (APRN) expansion of its on-demand meal kits at Costco (COST) continues to progress well, spreading to the Midwest and Southern areas of the U.S., and that this reinforces his increasingly constructive stance. While still small compared to direct-to-consumer, Yruma says the kits provide an opportunity for Blue Apron to conveniently reach new customers with a best-in-class national partner and that its upside prospects are becoming more favorable. Yruma maintains a Sector Weight rating, says valuation looks reasonable, and adds that operational issues at the Linden fulfillment centers are "largely in the past."
08/03/18
ADAM
08/03/18
NO CHANGE
Target $6
ADAM
Buy
Blue Apron downside risk limited at current levels, says Canaccord
Canaccord analyst Michael Graham noted Blue Apron reported mixed Q2 results and said the guidance suggests the revenue impact from the "transition" year will get worse in Q3 and Q4 before it gets better. Despite that, he sees reasons to be optimistic heading into 2019, including a likely return to intensive marketing and upside from nascent multi-channel offerings. Graham maintained his Buy rating and lowered his price target to $6 from $8 on Blue Apron shares.
FTV Fortive
$83.46

-0.54 (-0.64%)

03/08/18
BARD
03/08/18
UPGRADE
Target $57
BARD
Outperform
Altra Industrial Motion upgraded to Outperform at Baird
As reported previously, Baird analyst Michael Halloran upgraded Altra Industrial Motion (AIMC) to Outperform from Neutral. The analyst believes 2018 will be a year of transformation following its deal with Fortive (FTV). The analyst said the deal synergies appear reasonable and the potential accretion will be significant. Halloran raised his price target to $57 from $50 on Altra Industrial shares.
03/09/18
JPMS
03/09/18
DOWNGRADE
Target $84
JPMS
Neutral
Fortive downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Steve Tusa downgraded Fortive to Neutral with an $84 price target. The analyst believes the current valuation already reflects the company's upcoming capital deployment. He believes, however, that Fortive's "franchise quality remains intact."
06/27/18
WOLF
06/27/18
INITIATION
Target $90
WOLF
Outperform
Fortive initiated with an Outperform at Wolfe Research
Wolfe Research initiated Fortive with an Outperform and price target of $90.
09/04/18
WOLF
09/04/18
DOWNGRADE
WOLF
Peer Perform
Fortive downgraded to Peer Perform from Outperform at Wolfe Research
GTT GTT Communications
$41.90

-1.075 (-2.50%)

08/21/18
KEYB
08/21/18
NO CHANGE
Target $57
KEYB
Overweight
GTT Communications should be bought at current levels, says KeyBanc
KeyBanc analyst Brandon Nispel notes that with GTT Communications down 18.3% since its Q2 report, he finds current levels to be a buying opportunity. The analyst hosted GTT's General Counsel and EVP Chris McKee and came away from the conference more confident that the company will be able to continue pursuing its acquisition strategy to achieve synergies and growth. Nispel reiterates an Overweight rating and $57 price target on the shares.
08/06/18
BWSF
08/06/18
INITIATION
Target $5
BWSF
Sell
BWS starts GTT Communications with Sell rating, $5 price target
BWS Financial analyst Hamed Khorsand initiated coverage of GTT Communications with a Sell rating and $5 price target. The stock in morning trading is down 5.5%, or $2.23, to $38.18. GTT "has been rolling up Internet backbone companies in an effort to enhance its scale and presence in the industry, but it has come at a cost they can no longer afford," Khorsand tells investors in a research note. The analyst points out that GTT over 11 years has completed over 30 acquisitions. The company now has $3.2B in debt and has yet to report quarter where cash flow from operations would be able to cover capex, interest expense, and enough to make a principal debt payment, according to Khorsand. He believes the company's debt balance "could leave little value for the equity"
08/06/18
BWSF
08/06/18
INITIATION
Target $5
BWSF
Sell
GTT Communications initiated with a Sell at BWS Financial
Target $5.
08/06/18
WBLR
08/06/18
NO CHANGE
WBLR
Outperform
GTT Communications selloff Friday a buying opportunity, says William Blair
William Blair analyst Jim Breen views the 14% pullback in shares of GTT Communications on Friday as a buying opportunity. The analyst understands concerns around the company's recently elevated debt levels to fund the Interoute acquisition, as well as margin weakness and a slight sequential revenue decline in the quarter. The analyst, however, expects GTT to resume organic growth in the second half of the year. Further, with expanding margins and low capital-expenditure requirements, he estimates its free cash flow will continue to increase. Breen keeps an Outperform rating on GTT Communications and notes the Interoute acquisition will nearly double the size of the total company.
AG First Majestic
$5.37

-0.19 (-3.42%)

08/27/18
08/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. First Majestic (AG) upgraded to Outperform from Market Perform at BMO Capital with analyst Ryan Thompson citing his expectations of gross margin improvement following the shutdown of the high-cost La Guitarra mine and the integration of the high-margin San Dimas mine. 2. Papa John's (PZZA) upgraded to Buy from Neutral at Kalinowski with analyst Mark Kalinowski saying he believes the reported hiring of Bank of America and Lazard increases the odds of a favorable outcome over the next 12 months, including the possibility of an acquisition. 3. Portola Pharmaceuticals (PTLA) upgraded to Neutral from Underperform at Credit Suisse with analyst Vamil Divan citing Johnson & Johnson (JNJ) and Bayer's (BAYRY) presentation of disappointing data for Xarelto in the acute medically ill population at ESC. 4. Bancolombia (CIB) upgraded to Neutral from Sell at Citi. 5. AK Steel (AKS) and Steel Dynamics (STLD) were upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/15/18
TDSI
05/15/18
UPGRADE
TDSI
Buy
First Majestic upgraded to Buy from Hold at TD Securities
08/27/18
BMOC
08/27/18
UPGRADE
BMOC
Outperform
First Majestic upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Ryan Thompson upgraded First Majestic Silver to Outperform and raised his price target for the shares to C$9.50f from C$8.75.
08/27/18
BMOC
08/27/18
UPGRADE
Target $9.5
BMOC
Outperform
First Majestic upgraded at BMO Capital on margin improvement outlookup
As reported earlier, BMO Capital analyst Ryan Thompson upgraded First Majestic to Outperform from Market Perform and raised his price target to CAD9.50 from CAD8.75. The analyst cites his expectations of gross margin improvement following the shutdown of the high-cost La Guitarra mine and the integration of the high-margin San Dimas mine. Thompson also notes the possibility of a reversal in silver prices given the "crowded short position in precious metals" which would benefit the company.
WPX WPX Energy
$18.40

-0.67 (-3.51%)

07/05/18
TDSI
07/05/18
INITIATION
Target $25
TDSI
Buy
WPX Energy initiated with a Buy at TD Securities
TD Securities analyst Menno Hulshof initiated WPX Energy with a Buy and $25 price target.
08/03/18
GSCO
08/03/18
DOWNGRADE
Target $21
GSCO
Neutral
WPX Energy downgraded to Neutral from Conviction Buy at Goldman Sachs
Goldman Sachs analyst John Nelson downgraded WPX Energy (WPX) to Neutral and removed the shares from his firm's Conviction List. The analyst believes the company's secular growth outlook remains intact and cites valuation for the downgrade. WPX's valuation is less differentiated at current share levels, and investors should rotate into Diamondback Energy (FANG) and PDC Energy (PDCE), which offer greater upside potential, Nelson tells investors in a research note. The analyst has a $21 price target for WPX shares.
08/06/18
RAJA
08/06/18
UPGRADE
RAJA
Strong Buy
WPX Energy upgraded to Strong Buy from Outperform at Raymond James
08/06/18
RAJA
08/06/18
UPGRADE
Target $30
RAJA
Strong Buy
WPX Energy upgraded to Strong Buy at Raymond James
As previously reported, Raymond James upgraded WPX Energy to Strong Buy from Outperform and raised its price target to $30 from $25 following the solid beat and raise. Analyst John Freeman said WPX remains a high quality operator with significant exposure to top tier assets in the Delaware and Williston basins and should benefit significantly from the firm's expectations for higher Brent prices in 2019 relative to WTI/Midland.

TODAY'S FREE FLY STORIES

ETFC

E-Trade

$48.89

0.65 (1.35%)

09:25
02/23/19
02/23
09:25
02/23/19
09:25
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CAT

Caterpillar

$138.77

-0.08 (-0.06%)

, XRX

Xerox

$31.50

0.16 (0.51%)

08:29
02/23/19
02/23
08:29
02/23/19
08:29
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CAT

Caterpillar

$138.77

-0.08 (-0.06%)

XRX

Xerox

$31.50

0.16 (0.51%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$14.81

0.02 (0.14%)

F

Ford

$8.71

(0.00%)

GM

General Motors

$39.98

0.35 (0.88%)

HMC

Honda

$28.17

0.43 (1.55%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$121.84

0.66 (0.54%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$31.51

-0.62 (-1.93%)

LUV

Southwest

$53.62

-0.69 (-1.27%)

VZ

Verizon

$56.95

0.81 (1.44%)

TMUS

T-Mobile

$73.17

-0.09 (-0.12%)

T

AT&T

$31.15

0.32 (1.04%)

NOK

Nokia

$6.21

0.06 (0.98%)

ERIC

Ericsson

$9.51

0.285 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 03

    Mar

  • 03

    Mar

  • 04

    Mar

  • 11

    Mar

  • 13

    Mar

  • 20

    Mar

  • 27

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

AIMT

Aimmune

$23.70

0.73 (3.18%)

, AZN

AstraZeneca

$40.95

0.515 (1.27%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
The American Academy of Asthma, Allergy & Immunology to hold annual meeting »

AAAAI Annual Meeting 2019…

AIMT

Aimmune

$23.70

0.73 (3.18%)

AZN

AstraZeneca

$40.95

0.515 (1.27%)

TEVA

Teva

$17.28

0.03 (0.17%)

NVS

Novartis

$90.77

0.26 (0.29%)

DNA

Bought by RHHBY

$0.00

(0.00%)

SHPG

Shire

$0.00

(0.00%)

REGN

Regeneron

$422.43

3.77 (0.90%)

SNY

Sanofi

$41.20

-0.13 (-0.31%)

ALK

Alaska Air

$62.35

-0.48 (-0.76%)

ABT

Abbott

$76.40

1.26 (1.68%)

CVS

CVS Health

$62.00

-0.33 (-0.53%)

KALV

KalVista

$20.74

-0.04 (-0.19%)

BCRX

BioCryst

$8.99

0.32 (3.69%)

OPTN

Optinose

$7.31

0.02 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 04

    Mar

  • 04

    Mar

  • 04

    Mar

  • 07

    Mar

  • 11

    Mar

  • 11

    Mar

  • 12

    Mar

  • 18

    Mar

  • 19

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

  • 18

    May

ETFC

E-Trade

$48.89

0.65 (1.35%)

04:55
02/23/19
02/23
04:55
02/23/19
04:55
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

TEX

Terex

$35.29

-0.3 (-0.84%)

19:01
02/22/19
02/22
19:01
02/22/19
19:01
Hot Stocks
Terex to sell Demag Mobile Cranes business to Tadano for $215M enterprise value »

Terex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CZR

Caesars

$9.05

-0.37 (-3.93%)

18:34
02/22/19
02/22
18:34
02/22/19
18:34
Hot Stocks
Canyon Partners: Caesars shareholders' value best served by open sale process »

Canyon Partners issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$20.85

0.17 (0.82%)

, BA

Boeing

$424.05

6.57 (1.57%)

18:11
02/22/19
02/22
18:11
02/22/19
18:11
Periodicals
Brazilian judge suspends Embraer-Boeing deal talks, Reuters reports »

A Brazilian judge…

ERJ

Embraer

$20.85

0.17 (0.82%)

BA

Boeing

$424.05

6.57 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 14

    Mar

  • 28

    May

BXG

Bluegreen Vacations

$14.47

0.55 (3.95%)

18:02
02/22/19
02/22
18:02
02/22/19
18:02
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SM

SM Energy

$16.88

-0.13 (-0.76%)

17:57
02/22/19
02/22
17:57
02/22/19
17:57
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy's higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$37.22

-1.15 (-3.00%)

17:47
02/22/19
02/22
17:47
02/22/19
17:47
Syndicate
Breaking Syndicate news story on AutoNation »

AutoNation files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

TSLA

Tesla

$294.60

3.42 (1.17%)

, NSANY

Nissan

$0.00

(0.00%)

17:42
02/22/19
02/22
17:42
02/22/19
17:42
Periodicals
Tesla's Model 3 was the highest-selling EV globally in 2018, Verge reports »

Tesla's (TSLA) Model…

TSLA

Tesla

$294.60

3.42 (1.17%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFU

InfuSystem

$4.15

0.04 (0.97%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
InfuSystem announces settlement of derivative lawsuit »

InfuSystem Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALU

Kaiser Aluminum

$108.22

-1.9 (-1.73%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
Kaiser Aluminum names Neal West as new CFO »

Kaiser Aluminum announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$14.35

0.19 (1.34%)

17:00
02/22/19
02/22
17:00
02/22/19
17:00
Hot Stocks
Alder Biopharmaceuticals submits eptinezumab BLA to FDA »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

RF

Regions Financial

$16.24

-0.01 (-0.06%)

16:59
02/22/19
02/22
16:59
02/22/19
16:59
Syndicate
Breaking Syndicate news story on Regions Financial »

Regions Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

HL

Hecla Mining

$2.59

-0.145 (-5.31%)

16:58
02/22/19
02/22
16:58
02/22/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

, CELG

Celgene

$89.15

0.54 (0.61%)

16:52
02/22/19
02/22
16:52
02/22/19
16:52
Hot Stocks
Bristol-Myers files proxy statement in connection with proposed Celgene merger »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

CELG

Celgene

$89.15

0.54 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

  • 28

    May

TEN

Tenneco

$36.29

0.76 (2.14%)

16:48
02/22/19
02/22
16:48
02/22/19
16:48
Earnings
Tenneco sees FY19 revenue growth up 4%-5%, consensus $4.65B »

The company expects 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.